MedTrace Logo

Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

NCT01545037 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2017-07-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®

Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.

OTHER

Placebo

The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.

Sponsors & Collaborators

  • Sprim Advanced Life Sciences

    collaborator OTHER

  • Bio-K Plus International Inc.

    lead INDUSTRY

Principal Investigators

  • Dalia Perelman, MS,RD,CDE · SPRIM ALS

  • Syam P. Gaddam, MD · Digestive and Liver Disease Specialists A medical Group Inc.

  • Razming Krumian, DO · Westlake Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01545037 on ClinicalTrials.gov